Ophthalmic Drugs Conference 2019

SMi Group19 - 20 November 2019, London, UK.
The global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market.

With this in mind, this year's Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease; innovations in gene therapy; the challenges in drug delivery through a complex barrier; patient comfort and regulatory compliance which make up core components within the Ophthalmic Drug sphere.

New for 2019

The brand-new Focus Day on 'Novel Drug Delivery Through a Complex Barrier' will bring academic perspectives on the future for ocular drug delivery and notified bodies will provide a regulatory insight into this emerging field of ophthalmic drug development.

How will you benefit?

With over 15 expert presentations, the three-day agenda offers you peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more!

Network and learn from leading professionals such as:
Chairs for 2019

  • Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals
  • Naj Sharif, Vice President, Global Ophthalmology, Santen Inc, USA

Featured speakers include

  • Parisa Zamiri, Global Head of Clinical Development in Ophthalmology, Novartis Pharmaceutical Inc.
  • Gavin Spencer, Executive Vice President and Chief Business Officer, Nicox
  • AnizGirach, Chief Medical Officer, ProQR Therapeutics
  • Daniel Chung, Global Medical Strategy Lead- Ophthalmology, Spark Therapeutics
  • Michael Ehrlich, Senior Clinical Program Lead - Retinopathies, Boehringer Ingelheim
  • Peter Morgan-Warren, Medical Assessor, MHRA
  • William Dallman, Clinical Development Manager, Eyenuk

For more information and to register, please visit:
http://www.ophthalmicdrugs.com/WPNwb

Early-Bird Rates

  • Book by 28th June and save £300
  • Book by 30th September and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...